Point-of-care urine test for assessing adherence to isoniazid treatment for tuberculosis

References 1 Stone JH, Zen Y, Deshpande V. IgG4-related disease. N Eng J Med 2012; 366: 539–551. 2 Kanari H, Kagami S, Kashiwakuma D, et al. Role of Th2 cells in IgG4-related lacrimal gland enlargement. Int Arch Allergy Immunol 2010; 152: Suppl. 1, 47–53. 3 Tanaka A, Moriyama M, Nakashima H, et al. Th2 and regulatory immune reactions contribute to IgG4 production and the initiation of Mikulicz disease. Arthritis Rheum 2012; 64: 254–263. 4 Umehara H, Okazaki K, Masaki Y, et al. Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Mod Rheumatol 2012; 22: 21–30. 5 Umehara H, Okazaki K, Masaki Y, et al. A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details. Mod Rheumatol 2012; 22: 1–14. 6 Khosroshahi A, Bloch DB, Deshpande V, et al. Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease. Arthritis Rheum 2010; 62: 1755–1762. 7 Whittle BJ, Silverstein AM, Mottola DM, et al. Binding and activity of the prostacyclin receptor (IP) agonists, treprostinil and iloprost, at human prostanoid receptors: treprostinil is a potent DP1 and EP2 agonist. Biochem Pharmacol 2012; 84: 68–75. 8 Hata AN, Breyer RM. Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol Ther 2004; 103: 147–166. 9 Boswell MG, Zhou W, Newcomb DC, et al. PGI2 as a regulator of CD4+ subset differentiation and function. Prostaglandins Other Lipid Mediat 2011; 96: 21–26. 10 Kuo CH, Ko YC, Yang SN, et al. Effects of PGI2 analogues on Th1and Th2-related chemokines in monocytes via epigenetic regulation. J Mol Med 2011; 89: 29–41.